(North America, South America, and the Caribbean)
(Including Hong Kong SAR, Macau SAR, and Taiwan)
Novogene offers CLIA-validated Whole Exome Sequencing (WES) for investigation or diagnoses of genetic variations underlying cancers, Mendelian diseases, and complex human disorders.
Whole Exome Sequencing is gaining popularity as a viable and cost-effective alternative to Whole Genome Sequencing: WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of all disease-causing mutations.
Service Features
Clinical WES Workflow
Performance Metrics
Download Brochure to Learn More
Contact Us / Request Quote
I agree that Novogene Corporation may use this information to contact me to assist with my request. I understand that all personal information I have submitted will be kept confidential in accordance with Novogene's privacy policy.
8801 Folsom Blvd #290, Sacramento, CA 95826
Copyright©2011-2020 Novogene Corporation All Rights Reserved. Information and specifications are subject to change at any time without notice.
The field is required.